Menu

Who Makes Belzutifan: Welireg and Merck/ MSD Explained

Author: medicalhalo
Release time: 2026-11-20 04:24:09

  Belzutifan is the first-in-class oral HIF-2αinhibitor to reach market.The originator brand is Welireg,40mg tablets,dosed 120mg once daily,with or without food.

  Development lineage:The molecule(PT2977)came out of Peloton Therapeutics,building on the HIF-2αallosteric pocket identified at UT Southwestern.Merck acquired Peloton in 2019 and carried the program forward.On August 13,2021,the FDA approved Welireg under priority review for adults with von Hippel-Lindau disease–associated RCC,CNS hemangioblastoma,or pNET not requiring immediate surgery—the first HIF-2αinhibitor ever approved.

  Corporate identity:

  Group level:Merck&Co.,Inc.,operating as MSD​outside the US and Canada.

  Label/MAH level:Merck Sharp&Dohme LLC​(US)or Merck Sharp&Dohme(UK)Limited​and other local MSD entities.

  So“Merck/MSD/Merck Sharp&Dohme”all map to the same originator system,but marketing-authorization holders,packagers,and supply sites differ by country—do not collapse them into one factory.

  Originator vs.other brands:

  The originator is the product that first completed development and obtained approval—that is Welireg.Some overseas markets now list other belzutifan brands(e.g.,LUCIBELZU by Luoxus in Laos).To tell them apart,check beyond“belzutifan 40mg”:

  Brand name​on the carton—Welireg indicates originator;

  Manufacturer/MAH—is it an MSD/Merck Sharp&Dohme entity;

  Local registration number,approval status,batch number—verifiable in the destination regulator’s database;

  For non-originator versions,whether the local authority requires bioequivalence data,GMP certification,and traceability.

  Prices may differ across markets and brands,but price is not a quality proxy.

  Safety note:Belzutifan can cause severe hypoxia—monitor SpO₂by pulse oximetry before and frequently during early treatment;grade 2 hypoxia warrants oxygen and reassessment,grade 3 holds therapy and considers dose reduction,grade 4 is permanent discontinuation.Anemia,fatigue,nausea,and embryo-fetal toxicity also apply;contraception is required for people of reproductive potential.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。

Belzutifan
描述
Belzutifan is an oral small molecule hypoxia-inducible factor-2α (HIF-2α) inhibitor that targets and inhibits the activity of HIF-2α and blocks its in [ 详情 ]
微信在线客服